Welcome to our dedicated page for ResMed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on ResMed stock.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in digital health and cloud-connected medical devices, focusing on innovative solutions that treat and prevent respiratory conditions like sleep apnea and COPD. By transforming patient care, ResMed empowers individuals to live healthier, higher-quality lives. Their diverse product portfolio includes flow generators, masks, and accessories designed to keep patients out of hospitals and manage chronic diseases effectively.
Operating in over 140 countries, ResMed’s cloud-connected medical devices provide data-driven insights used by patients, healthcare providers, and payers to deliver personalized and efficient healthcare. Their comprehensive out-of-hospital software platforms support professionals and caregivers, enhancing the quality of life and reducing healthcare costs. The company earns about two-thirds of its revenue from the Americas, with the remainder coming from Europe, Japan, and Australia.
In recent developments, ResMed successfully defended its intellectual property against a patent infringement claim by NYU, with the PTAB ruling in favor of ResMed on all challenged claims. This outcome underscores the company’s commitment to innovation, backed by over 9,500 issued or pending patents and designs.
ResMed also made headlines with a global field action to update guides for masks with magnets, ensuring user safety around medical implants. Their proactive approach and dedication to patient safety were evident as they addressed potential magnetic interference issues without necessitating a product recall.
Financially, ResMed continues to demonstrate strong growth. In the second quarter of fiscal year 2024, the company reported double-digit growth across its devices, masks, accessories, and residential care software businesses. This robust performance highlights ResMed’s strategic focus on expanding its product offerings and maintaining cost discipline.
ResMed's latest product launch, the AirCurve 11 series, further showcases their commitment to innovation. These bilevel PAP devices feature advanced digital technology to improve patient comfort and compliance, addressing challenges in CPAP therapy adaptation.
Continuing its leadership in respiratory care, ResMed actively participates in significant industry conferences such as the American Thoracic Society International Conference and SLEEP 2024, presenting crucial research on sleep disorders and their impact on health. This research supports the effectiveness of PAP therapy in reducing mortality and improving patient outcomes, solidifying ResMed’s role as a pioneer in the field.
With a clear focus on enhancing patient care through technology and innovation, ResMed is well-positioned to lead the expansion of sleep and respiratory health.
Avant Technologies has entered a joint venture with Ainnova Tech to form Ai-nova Acquisition Corp (AAC), focusing on AI-powered healthcare solutions. The partnership will commercialize Ainnova's VisionAI platform and retinal cameras in North America and Europe. VisionAI can detect diabetic retinopathy and other diseases through retinal scans with high accuracy. With the global healthcare AI market projected to reach $188 billion by 2030, this venture aims to make retinal scanning a standard in primary care. The technology addresses a critical need, as 30% of 500 million diabetics globally may develop diabetic retinopathy, while there's a shortage of ophthalmologists.
ResMed (NYSE: RMD, ASX: RMD) announced that Chairman and CEO Mick Farrell and Chief Medical Officer Dr. Carlos Nunez will participate in a fireside chat at the UBS Global Healthcare Conference. The event will take place on November 12, 2024, at 3:30 p.m. PST at the Terranea Resort Hotel in Rancho Palos Verdes, CA. A live audio-only webcast will be available on the investor relations website, with a replay accessible for 30 days following the event.
ResMed reported strong Q1 FY2025 results with 11% year-over-year revenue growth to $1.2 billion. The company achieved significant improvements in profitability with operating profit up 34% and non-GAAP operating profit increasing 27%. Gross margin improved 420 basis points to 58.6%, while operating cash flow reached $326 million. Diluted earnings per share grew to $2.11, with non-GAAP EPS at $2.20. Growth was driven by increased demand for sleep devices and masks, along with strong performance in the Residential Care Software business. The company declared a quarterly dividend of $0.53 per share.
ResMed (NYSE: RMD, ASX: RMD) has announced plans to release its financial and operational results for the first quarter of fiscal year 2025. The release is scheduled for Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. This announcement provides investors and analysts with a specific date to anticipate the company's quarterly performance update, which is important for assessing ResMed's financial health and market position in the medical equipment industry.
ResMed (NYSE: RMD, ASX: RMD) unveiled its 2030 Strategy at an Investor Day in New York City, aiming to drive growth, profitability, and shareholder returns. The company's ambition is to help over 500 million people achieve their full health potential by 2030. ResMed introduced an updated five-year financial outlook, expecting high-single-digit revenue growth and earnings growth higher than revenue growth.
The 2030 Strategy focuses on three pillars: growing the core sleep apnea franchise, capitalizing on opportunities in broader sleep and breathing health, and investing 7% of revenue into R&D to create an integrated digital ecosystem for home health technology. ResMed plans to leverage its leadership in connected digital health, transforming sleep health, breathing health, and health tech at home through innovative products and digital solutions.
ResMed (NYSE: RMD, ASX: RMD) has launched the AirTouch™ N30i, its first fabric-wrapped CPAP mask. This innovative nasal mask features a soft, breathable, and moisture-wicking design for optimal comfort in a tube-up configuration. The AirTouch N30i combines softness, breathability, and a high-performance seal to deliver exceptional comfort.
In a multi-center study with experienced CPAP users, 92.6% preferred AirTouch N30i for long-term use, and 96.7% rated it appealing or very appealing for its look and feel. The mask incorporates a ComfiSoft™ cushion and fabric-wrapped frame with a fabric seal design coated over silicone. Available in three cushion sizes and two frame sizes, it offers a customized fit. The AirTouch N30i will be available in the U.S. beginning the week of October 28, 2024.
ResMed (NYSE: RMD, ASX: RMD) has unveiled new digital and personalized solutions to improve sleep health. The company has integrated its myAir consumer app with Apple and Android smartwatches, introduced a Generative AI-enabled sleep health assistant named Dawn, and launched new travel gear for CPAP users.
Key features of the updated myAir app include:
- Smartwatch compatibility
- Sleep staging integration
- Personalized coaching
- Holistic health trends
The LUXE range of travel bags for CPAP users will be available in quantities from October 28. These innovations aim to enhance therapy engagement and improve overall health outcomes for sleep apnea patients.
ResMed (NYSE: RMD, ASX: RMD) has announced its 2024 Investor Day, scheduled for September 30, 2024, at the New York Stock Exchange. The event will commence at approximately 1:00 p.m. Eastern Daylight Time and will be accessible both in-person and via a virtual webcast.
This investor day will provide insights into ResMed's 2030 strategy aimed at accelerating growth. Interested parties can find more information, including the live webcast link and an RSVP option for in-person attendance, on the company's investor relations website. A replay of the webcast will be available for 30 days following the event.
ResMed presented 18 supported studies at ERS 2024, including research projecting the impact of vaping, smoking, and air pollution on COPD in Western Europe. Key findings include:
- 88.7 million new COPD hospitalizations projected across Western Europe between 2019-2050
- Vaping projected to incur almost €30 billion additional costs by 2050
- €4.9 trillion projected cumulative cost to support COPD lung conditions by 2050
- 16% projected reduction in risk of death after severe exacerbation for COPD patients using home NIV support
The research highlights the significant health and economic burden of COPD, exacerbated by environmental and behavioral factors. Home non-invasive ventilation (NIV) was found to reduce mortality risk in COPD patients.
ResMed (NYSE: RMD, ASX: RMD) has announced that Chairman and CEO Mick Farrell and Chief Medical Officer Dr. Carlos Nunez will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Wednesday, September 4, 2024, at approximately 10:00 a.m. EDT at the New York Marriott Marquis.
Investors and interested parties can access the live, audio-only webcast through ResMed's investor relations website. A replay of the webcast will be available for 30 days following the event, accessible approximately 24 hours after the live session ends.
FAQ
What is the current stock price of ResMed (RMD)?
What is the market cap of ResMed (RMD)?
What does ResMed Inc. specialize in?
Where does ResMed operate?
What are some of ResMed’s recent key developments?
How does ResMed ensure patient safety with its products?
What financial performance did ResMed report recently?
What innovations has ResMed introduced recently?
How does ResMed contribute to healthcare research?
What is ResMed’s approach to out-of-hospital care?
What kind of products does ResMed develop?
How does ResMed support its innovation?
